155 related articles for article (PubMed ID: 23510598)
1. Molecular markers to predict outcome to antiangiogenic therapies in colorectal cancer: current evidence and future perspectives.
Custodio A; Barriuso J; de Castro J; Martínez-Marín V; Moreno V; Rodríguez-Salas N; Feliu J
Cancer Treat Rev; 2013 Dec; 39(8):908-24. PubMed ID: 23510598
[TBL] [Abstract][Full Text] [Related]
2. Antiangiogenic cancer therapies get their act together: current developments and future prospects of growth factor- and growth factor receptor-targeted approaches.
Gille J
Exp Dermatol; 2006 Mar; 15(3):175-86. PubMed ID: 16480425
[TBL] [Abstract][Full Text] [Related]
3. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
Grothey A; Ellis LM
Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
[TBL] [Abstract][Full Text] [Related]
4. The evolving role of VEGF-targeted therapies in the treatment of metastatic colorectal cancer.
Fakih M
Expert Rev Anticancer Ther; 2013 Apr; 13(4):427-38. PubMed ID: 23432698
[TBL] [Abstract][Full Text] [Related]
5. Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer.
Troiani T; Martinelli E; Orditura M; De Vita F; Ciardiello F; Morgillo F
Expert Opin Investig Drugs; 2012 Jul; 21(7):949-59. PubMed ID: 22612461
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenesis agents in colorectal cancer.
Hubbard J; Grothey A
Curr Opin Oncol; 2010 Jul; 22(4):374-80. PubMed ID: 20375894
[TBL] [Abstract][Full Text] [Related]
7. Future directions in the use of antiangiogenic agents in patients with colorectal cancer.
Hoff PM
Semin Oncol; 2004 Dec; 31(6 Suppl 17):17-21. PubMed ID: 15696026
[TBL] [Abstract][Full Text] [Related]
8. Future directions in vascular endothelial growth factor-targeted therapy for metastatic colorectal cancer.
Grothey A
Semin Oncol; 2006 Oct; 33(5 Suppl 10):S41-9. PubMed ID: 17145524
[TBL] [Abstract][Full Text] [Related]
9. [Anti-angiogenic treatment and colorectal cancer].
André T; Tournigand C; Abbas F; Louvet C; de Gramont A;
Bull Cancer; 2007 Jul; 94 Spec No():S211-9. PubMed ID: 17846007
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab in colorectal cancer: current and future directions.
Yeung Y; Tebbutt NC
Expert Rev Anticancer Ther; 2012 Oct; 12(10):1263-73. PubMed ID: 23113577
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers to predict the clinical efficacy of bevacizumab in cancer.
Jubb AM; Harris AL
Lancet Oncol; 2010 Dec; 11(12):1172-83. PubMed ID: 21126687
[TBL] [Abstract][Full Text] [Related]
12. Assessing the in vivo efficacy of biologic antiangiogenic therapies.
Wilson PM; LaBonte MJ; Lenz HJ
Cancer Chemother Pharmacol; 2013 Jan; 71(1):1-12. PubMed ID: 23053262
[TBL] [Abstract][Full Text] [Related]
13. Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer.
Chase JL
Pharmacotherapy; 2008 Nov; 28(11 Pt 2):23S-30S. PubMed ID: 18980549
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic drugs currently used for colorectal cancer: what other pathways can we target to prolong responses?
Abbadessa G; Vogiatzi P; Rimassa L; Claudio PP
Drug News Perspect; 2007 Jun; 20(5):307-13. PubMed ID: 17878958
[TBL] [Abstract][Full Text] [Related]
15. Antiangiogenic drugs for colorectal cancer: exploring new possibilities.
Ferrarotto R; Hoff PM
Clin Colorectal Cancer; 2013 Mar; 12(1):1-7. PubMed ID: 22763196
[TBL] [Abstract][Full Text] [Related]
16. Drug insight: antiangiogenic therapies for gastrointestinal cancers--focus on monoclonal antibodies.
Reinacher-Schick A; Pohl M; Schmiegel W
Nat Clin Pract Gastroenterol Hepatol; 2008 May; 5(5):250-67. PubMed ID: 18382435
[TBL] [Abstract][Full Text] [Related]
17. [Bevacizumab. Progress in cancer therapy by antiangiogenesis].
Krämer I; Lipp HP
Med Monatsschr Pharm; 2006 Jul; 29(7):249-54; quiz 255-6. PubMed ID: 16866078
[TBL] [Abstract][Full Text] [Related]
18. Circulating endothelial cells and their subpopulations: role as predictive biomarkers in antiangiogenic therapy for colorectal cancer.
Manzoni M; Comolli G; Torchio M; Mazzini G; Danova M
Clin Colorectal Cancer; 2015 Mar; 14(1):11-7. PubMed ID: 25591800
[TBL] [Abstract][Full Text] [Related]
19. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer.
Los M; Roodhart JM; Voest EE
Oncologist; 2007 Apr; 12(4):443-50. PubMed ID: 17470687
[TBL] [Abstract][Full Text] [Related]
20. Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients.
Watanabe T; Kobunai T; Yamamoto Y; Matsuda K; Ishihara S; Nozawa K; Iinuma H; Ikeuchi H
Dis Colon Rectum; 2011 Aug; 54(8):1026-35. PubMed ID: 21730794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
